Developmental genes and cancer in children

Pediatric Blood and Cancer

Volumn 52, Issue 7, 2009, Pages 755-760

  Moore, Sam W ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Cancer; Children; Development; Genes; Oncogenes

Indexed keywords

BETA CATENIN; POLYCOMB GROUP PROTEIN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BRAIN TUMOR; CANCER CELL CULTURE; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CHILDHOOD CANCER; CHROMATIN STRUCTURE; CHROMOSOME ABERRATION; DEVELOPMENTAL GENE; DNA METHYLATION; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; EWING SARCOMA; FETUS DEVELOPMENT; GENE CONTROL; GENE FUNCTION; GENE MUTATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GERM LINE; GRANULAR CELL TUMOR; HEPATOBLASTOMA; HEREDITY; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HOMEOBOX; HUMAN; LEUKEMIA; LYMPHOCYTE TRANSFORMATION; METHYLATION; NEPHROBLASTOMA; NEUROBLASTOMA; ONCOGENE; PERINATAL PERIOD; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GENES, DEVELOPMENTAL; HUMANS; INFANT; NEOPLASMS;

EID: 67650496613     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21831     Document Type: Review

References (84)

1. Grandjean P. Late insights into early origins of disease. Basic Clin Pharmacol Toxicol 2008;102:94-99. (Pubitemid 351143424)
2. Scotting PJ,Walker DA, Perilongo G. Childhood solid tumours: A developmental disorder. Nat Rev Cancer 2005;5:481-488. (Pubitemid 40791490)
3. Hanson MA, Gluckman PD. Developmental origins of health and disease: New insights. Basic Clin Pharmacol Toxicol 2008;102: 90-93. (Pubitemid 351143434)
4. Soto AM, MaffiniMV, Sonnenschein C. Neoplasia as development gone awry: The role of endocrine disruptors. Int J Androl 2008;31:288-293. (Pubitemid 351341363)
5. Cohnheim J. Congenitales quergeskreiftes Muskelsarcon der Nieren. Virchows Arch 1875;64-65.
6. Soto AM, Vandenberg LN, Maffini MV, et al. Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 2008;102:125-133.
7. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol 2004;57:561-576. (Pubitemid 38725755)
8. Grandjean P, Weihe P. Developmental origins of environmentally induced disease and dysfunction International Conference on Foetal Programming and Developmental Toxicity, Torshavn, Faroe Islands, 20-24 May, 2007. Basic Clin Pharmacol Toxicol 2008; 102:71-72. (Pubitemid 351143426)
9. Potter VR. Phenotypic diversity in experimental hepatomas: The concept of partially blocked ontogeny. The 10th Walter Hubert Lecture. Br J Cancer 1978;38:1-23.
10. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: Prospects for therapy by directing differentiation. Cancer Res 1988;48:1996-2004. (Pubitemid 18104607)
11. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994;70:6-22. (Pubitemid 24080100)
12. Rankin J, Silf KA, Pearce MS, et al. Congenital anomaly and childhood cancer: A population-based, record linkage study. Pediatr Blood Cancer 2008;51:608-612.
13. Altmann AE, Halliday JL, Giles GG. Associations between congenital malformations and childhood cancer: A register-based case-control study. Br J Cancer 1998;78:1244-1249. (Pubitemid 28479159)
14. Halperin EC. Neonatal neoplasms. Int J Radiat Oncol Biol Phys 2000;47:171-178.
15. Moore SW. Genetic and clinical associations of neonatal tumours. In: Puri P, editor. Neonatal tumours. London: Springer; 1996. pp 11-22.
16. Chow EJ, Friedman DL, Mueller BA. Maternal and perinatal characteristics in relation to neuroblastoma. Cancer 2007;109: 983-992. (Pubitemid 46333540)
17. Berbel Tornero O, Ortega Garcia JA, Tortajada J, et al. Neonatal tumours and congenital malformations. An Pediatr (Barc) 2008; 68:589-595.
18. Munzer C, Menegaux F, Lacour B, et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: The ESCALE study (SFCE). Int J Cancer 2008; 122:2315-2321. (Pubitemid 351542337)
19. Cucina A, Biava PM,D'Anselmi F, et al. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis 2006;11:1617-1628. (Pubitemid 44253678)
20. Bishop JM. Molecular themes in oncogenesis. Cell 1991;64:235-248.
21. Felsher DW. Reversibility of oncogene-induced cancer. Curr Opin Genet Dev 2004;14:37-42.
22. Yang Q, Kiernan CM, Tian Y, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191-3197.
23. Shachaf CM, Gentles AJ, Elchuri S, et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 2008;68:5132-5142.
24. Felsher DW. Putting oncogenes into a developmental context. Cancer Biol Ther 2004;3:942-944.
25. Hersh JH, Angle B, Fox TL, et al. Developmental field defects: Coming together of associations and sequences during blastogenesis. Am J Med Genet 2002;110:320-323. (Pubitemid 34701045)
26. JorgensenHF, Giadrossi S, CasanovaM, et al. Stem cells primed for action: Polycomb repressive complexes restrain the expression of lineage-specific regulators in embryonic stem cells. Cell Cycle 2006;5:1411-1414. (Pubitemid 44153649)
27. Yauk C, Polyzos A, Rowan-Carroll A, et al. Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. Proc Natl Acad Sci USA 2008;105:605-610.
28. Mori H, Colman SM, Xiao Z, et al. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-8247. (Pubitemid 34651037)
29. Malinge S, Ragu C, la-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia Blood E Published 8-28-2008.
30. Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood E published 8-18-2008.
31. Toguchida J, Ishizaki K, Sasaki MS, et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 1989;338:156-158. (Pubitemid 19074104)
32. Schroeder WT, Chao LY, Dao DD, et al. Nonrandom loss of maternal chromosome 11 alleles in Wilms tumors. Am J Hum Genet 1987;40:413-420. (Pubitemid 17096943)
33. Duesberg P, Li R, Fabarius A, et al. Aneuploidy and cancer: From correlation to causation. Contrib Microbiol 2006;13:16-44.
34. Satge D, Sasco AJ, Carlsen NL, et al. A lack of neuroblastoma in Down syndrome: A study from 11 European countries. Cancer Res 1998;58:448-452. (Pubitemid 28087405)
35. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature E publication 8-24-2008.
36. Kushner BH, Cheung NK. Neuroblastoma-linking a common allele to a rare disease. N Engl J Med 2008;358:2635-2637. (Pubitemid 351831367)
37. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004;51:1-28. (Pubitemid 38781748)
38. Nijland MJ, Ford SP, Nathanielsz PW. Prenatal origins of adult disease. Curr Opin Obstet Gynecol 2008;20:132-138.
39. Torres-Montaner A, Hughes D. A hypothetical anti-neoplastic mechanism associated to reserve cells. J Theor Biol 2004;231: 239-248. (Pubitemid 39221876)
40. Collas P, Noer A, Timoskainen S. Programming the genome in embryonic and somatic stem cells. J Cell Mol Med 2007;11:602-620. (Pubitemid 47313312)
41. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet 2007;8:263-271.
42. Hartkamp J, Roberts SG. The role of theWilms' tumour-suppressor protein WT1 in apoptosis. Biochem Soc Trans 2008;36:629-631.
43. Morrison DJ, Kim MK, Berkofsky-FesslerW, et al. WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Mol Cancer Res 2008;6:1225-1231.
44. Grimaud C, Negre N, Cavalli G. From genetics to epigenetics: The tale of polycomb group and trithorax group genes. Chromosome Res 2006;14:363-375.
45. Mahmoudi T, Verrijzer CP. Chromatin silencing and activation by polycomb and trithorax group proteins. Oncogene 2001;20:3055-3066. (Pubitemid 32553560)
46. Ballestar E, Esteller M. Chapter 9 epigenetic gene regulation in cancer. Adv Genet 2008;61:247-267.
47. Arsic D, Qi BQ, Beasley SW. Hedgehog in the human: A possible explanation for the VATER association. J Paediatr Child Health 2002;38:117-121. (Pubitemid 34595557)
48. Arsic D,Keenan J, Quan QB, et al. Differences in the levels of sonic hedgehog protein during early foregut development caused by exposure to adriamycin give clues to the role of the Shh gene in oesophageal atresia. Pediatr Surg Int 2003;19:463-466. (Pubitemid 37092743)
49. Hatton BA, Knoepfler PS, Kenney AM, et al. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 2006;66:8655-8661. (Pubitemid 44449181)
50. Arsic D, BeasleySW, Sullivan MJ. Switched-on sonic hedgehog:A gene whose activity extends beyond fetal development-to oncogenesis. J Paediatr Child Health 2007;43:421-423. (Pubitemid 46802254)
51. Barisone GA, Yun JS, Diaz E. From cerebellar proliferation to tumorigenesis: New insights into the role of Mad3. Cell Cycle 2007;7:423-427.
52. Lee Y, Kawagoe R, Sasai K, et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 2007;26:6442-6447. (Pubitemid 47494220)
53. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24. (Pubitemid 36627817)
54. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 2003;83:429-434. (Pubitemid 36351004)
55. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003;94:575-581. (Pubitemid 36975010)
56. Paul S, Dey A. Wnt signaling and cancer development: Therapeutic implication. Neoplasma 2008;55:165-176.
57. D'Orazio D, MullerPY, Heinimann K, et al. Overexpression of Wnt target genes in adenomas of familial adenomatous polyposis patients. Anticancer Res 2002;22:3409-3414. (Pubitemid 36070122)
58. Ramburan A, Oladiran F, Smith C, et al. Microsatellite analysis of the adenomatous polyposis coli (APC) gene and immunoexpression of beta catenin in nephroblastoma: A study including 83 cases treated with preoperative chemotherapy. J Clin Pathol 2005;58: 44-50. (Pubitemid 40070495)
59. Udatsu Y, Kusafuka T, Kuroda S, et al. High frequency of betacatenin mutations in hepatoblastoma. Pediatr Surg Int 2001;17: 508-512. (Pubitemid 32896309)
60. Jeng YM, Wu MZ, Mao TL, et al. Somatic mutations of betacatenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000;152:45-51. (Pubitemid 30169017)
61. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-273. (Pubitemid 29048850)
62. Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 2001; 7:901-908. (Pubitemid 32708728)
63. Kusafuka T, Miao J, Kuroda S, et al. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor. Int J Mol Med 2002;10:395-399.
64. Kato N, Shibuya H, Fukase M, et al. Involvement of adenomatous polyposis coli (APC) gene in testicular yolk sac tumor of infants. Hum Pathol 2006;37:48-53. (Pubitemid 41790502)
65. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives. Semin Liver Dis 1999;19:253-262. (Pubitemid 29488768)
66. Pazianos G, Uqoezwa M, Reya T. The elements of stem cell selfrenewal: A genetic perspective. Biotechniques 2003;35:1240-1247. (Pubitemid 37517503)
67. Reya T. Regulation of hematopoietic stem cell self-renewal. Recent Prog Horm Res 2003;58:283-295. (Pubitemid 37339314)
68. Liu X, Mazanek P, Dam V, et al. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2007;27:1478-1488.
69. Calvisi DF, Factor VM, Ladu S, et al. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004;126:1374-1386. (Pubitemid 38552801)
70. Caramel J, Medjkane S, Quignon F, et al. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene 2007;27:2035-2044.
71. Guidi CJ, Sands AT, Zambrowicz BP, et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001;21:3598-3603. (Pubitemid 32381795)
72. Sevenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotypephenotype correlations. Hum Mol Genet 1999;8:2359-2368.
73. Sevenet N, Sheridan E, Amram D, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers.AmJ Hum Genet 1999;65:1342-1348.
74. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394: 203-206. (Pubitemid 28325977)
75. Fujisawa H, Misaki K, Takabatake Y, et al. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/ INI1 gene inactivation. J Neurooncol 2005;73:117-124. (Pubitemid 40974031)
76. Choi HK, Choi KC, Oh SY, et al. The functional role of the CARM1-SNF5 complex and its associated HMT activity in transcriptional activation by thyroid hormone receptor. Exp Mol Med 2007;39:544-555. (Pubitemid 47443869)
77. Sansam CG, Roberts CW. Epigenetics and cancer: Altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 2006;5:621-624.
78. Li X, Zhao X. Epigenetic regulation of mammalian stem cells. Stem Cells Dev E published 3-17-2008.
79. Banelli B, Di Vinci A, Gelvi I, et al. DNA methylation in neuroblastic tumors. Cancer Lett 2005;228:37-41.
80. Vasudevan SA, Nuchtern JG. Gene profiling of high risk neuroblastoma. World J Surg 2005;29:317-324. (Pubitemid 40768044)
81. Lazcoz P, Munoz J, Nistal M, et al. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 2006;6:254. (Pubitemid 44712383)
82. van Noesel MM, van Bezouw S, Voute PA, et al. Clustering of hypermethylated genes in neuroblastoma. Genes Chromosomes Cancer 2003;38:226-233.
83. Banelli B, Gelvi I, Di Vinci A, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-5628. (Pubitemid 43119355)
84. Grandjean P, Bellinger D, Bergman A, et al. The Faroes statement: Human health effects of developmental exposure to chemicals in our environment. Basic Clin Pharmacol Toxicol 2008;102: 73-75. (Pubitemid 351143418)